Quick Answer
AIM ImmunoTech Inc. reported Operating Income Loss of -$11.66 million for the year ending 2025.
- AIM ImmunoTech Inc. showed an increase of +41.0% in Operating Income Loss from 2024 to 2025.
- This data is from AIM ImmunoTech Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: -$3.59 million | Q2 2011: -$3.25 million | Q3 2011: -$3.56 million | Q1 2012: -$3.75 million | Q2 2012: -$3.63 million | Q3 2012: -$4.97 million | Q1 2013: -$4.56 million | Q2 2013: -$4.73 million | Q3 2013: -$4.46 million | Q1 2014: -$5.11 million | Q2 2014: -$5.09 million | Q3 2014: -$4.33 million | Q1 2015: -$4.92 million | Q2 2015: -$4.90 million | Q3 2015: -$3.98 million | Q1 2016: -$3.68 million | Q2 2016: -$2.81 million | Q3 2016: -$3.23 million | Q1 2017: -$3.24 million | Q2 2017: -$2.73 million | Q3 2017: -$2.65 million | Q1 2018: -$2.57 million | Q2 2018: -$3.23 million | Q3 2018: -$3.04 million | Q1 2019: -$2.93 million | Q2 2019: -$3.22 million | Q3 2019: -$3.21 million | Q1 2020: -$3.33 million | Q2 2020: -$3.34 million | Q3 2020: -$3.36 million | Q1 2021: -$3.75 million | Q2 2021: -$3.72 million | Q3 2021: -$3.93 million | Q1 2022: -$3.15 million | Q2 2022: -$4.70 million | Q3 2022: -$6.52 million | Q1 2023: -$4.30 million | Q2 2023: -$5.46 million | Q3 2023: -$8.16 million | Q1 2024: -$5.73 million | Q2 2024: -$3.69 million | Q3 2024: -$4.49 million | Q1 2025: -$3.62 million | Q2 2025: -$2.65 million | Q3 2025: -$2.45 million.
- Over the full 17 years of available data (2009 to 2025), AIM ImmunoTech Inc.'s Operating Income Loss has grown by 12.1%.
- Historical annual values: Fiscal year 2025: -$11.66 million | Fiscal year 2024: -$19.77 million | Fiscal year 2023: -$31.92 million | Fiscal year 2022: -$19.92 million | Fiscal year 2021: -$18.84 million | Fiscal year 2020: -$15.15 million | Fiscal year 2019: -$12.44 million | Fiscal year 2018: -$11.50 million | Fiscal year 2017: -$11.42 million | Fiscal year 2016: -$13.80 million | Fiscal year 2015: -$16.65 million | Fiscal year 2014: -$19.10 million | Fiscal year 2013: -$17.17 million | Fiscal year 2012: -$20.34 million | Fiscal year 2011: -$14.30 million | Fiscal year 2010: -$16.39 million | Fiscal year 2009: -$13.26 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: